UsAgainstAlzheimer’s Applauds Eisai and Biogen for their Progress Toward a Disease-Modifying Drug

UsAgainstAlzheimer’s Chairman George Vradenburg today issued the following statement regarding the report today by Eisai and Biogen at the Alzheimer’s Association International Conference (AAIC) that their Alzheimer’s Drug BAN2401 demonstrated positive results in a Phase II clinical trial.


“UsAgainstAlzheimer’s is pleased to see the positive results Eisai and Biogen reported today on their Phase II trial for the Alzheimer’s drug, BAN2401. These promising results of the most recent BAN2401 study bring welcome hope to the Alzheimer’s community and demonstrate the vital importance of persistent and patient investments in the innovative medicines needed by the tens of millions of families around the world experiencing this disease.


“This news is an important reminder that despite the difficulties and setbacks that the field has experienced in Alzheimer’s drug development, with perseverance, we can illuminate the complexities of this disease and eventually find a disease-modifying medicine.  


“Eisai and Biogen have been steadfast in their commitment to innovation in the Alzheimer’s space.  We welcome the opportunity to bet, with them, on their success and to ready the marketplace for rapid adoption of their product if, as and when approved for marketing. While those at Eisai and Biogen are doing their part to combat Alzheimer’s disease, the war against this disease cannot be won by them alone.


“While we should all celebrate signs of progress, victories come too with added responsibility for each of us to focus our time and resources on assuring a clear path to better outcomes for families experiencing this disease. The disease is a shared problem that requires shared solutions.”